Rainer Schneider

Bio: Rainer Schneider is an academic researcher from University of Freiburg. The author has contributed to research in topics: Placebo & Arsenicum album. The author has an hindex of 11, co-authored 19 publications receiving 642 citations.

Mercury and autism: accelerating evidence?

Abstract: The causes of autism and neurodevelopmental disorders are unknown. Genetic and environmental risk factors seem to be involved. Because of an observed increase in autism in the last decades, which parallels cumulative mercury exposure, it was proposed that autism may be in part caused by mercury. We review the evidence for this proposal. Several epidemiological studies failed to find a correlation between mercury exposure through thimerosal, a preservative used in vaccines, and the risk of autism. Recently, it was found that autistic children had a higher mercury exposure during pregnancy due to maternal dental amalgam and thimerosal-containing immunoglobulin shots. It was hypothesized that children with autism have a decreased detoxification capacity due to genetic polymorphism. In vitro, mercury and thimerosal in levels found several days after vaccination inhibit methionine synthetase (MS) by 50%. Normal function of MS is crucial in biochemical steps necessary for brain development, attention and production of glutathione, an important antioxidative and detoxifying agent. Repetitive doses of thimerosal leads to neurobehavioral deteriorations in autoimmune susceptible mice, increased oxidative stress and decrease d intracellular levels of glutathione in vitro. Subsequently, autistic children have significantly decreased level of reduced glutathione. Promising treatments of autism involve detoxification of mercury, and supplementation of deficient metabolites.

Alzheimer disease: mercury as pathogenetic factor and apolipoprotein E as a moderator

Abstract: The etiology of most cases of Alzheimer’s disease (AD) is as yet unknown. Epidemiological studies suggest that environmental factors may be involved beside genetic risk factors. Some studies have shown higher mercury concentrations in brains of deceased and in blood of living patients with Alzheimer’s disease. Experimental studies have found that even smallest amounts of mercury but no other metals in low concentrations were able to cause all nerve cell changes, which are typical for Alzheimer’s disease. The most important genetic risk factor for sporadic Alzheimer’s disease is the presence of the apolipoprotein Ee4 allele whereas the apolipoprotein Ee2 allele reduces the risk of developing Alzheimer’s disease. Some investigators have suggested that apolipoprotein Ee4 has a reduced ability to bind metals like mercury and therefore explain the higher risk for Alzheimer’s disease. Therapeutic approaches embrace pharmaceuticals which bind metals in the brain of patients with Alzheimer’s disease. In sum, both the findings from epidemiological and demographical studies, the frequency of amalgam application in industrialized countries, clinical studies, experimental studies and the dental state of AD patients in comparison to controls suggest a decisive role for inorganic mercury in the etiology of AD.

Distant intentionality and the feeling of being stared at: two meta-analyses.

Abstract: Findings in parapsychology suggest an effect of distant intentionality. Two laboratory set-ups explored this topic by measuring the effect of a distant intention on psychophysiological variables. The 'Direct Mental Interaction in Living Systems' experiment investigates the effect of various intentions on the electrodermal activity of a remote subject. The 'Remote Staring' experiment examines whether gazing by an observer covaries with the electrodermal activity of the person being observed. Two meta-analyses were conducted. A small significant effect size (d =.11, p =.001) was found in 36 studies on 'direct mental interaction', while a best-evidence-synthesis of 7 studies yielded d =.05 (p =.50). In 15 remote staring studies a mean effect size of d = 0.13 (p =.01) was obtained. It is concluded that there are hints of an effect, but also a shortage of independent replications and theoretical concepts.

Cognitive Bias of Optimism and its Influence on Psychological Well-Being

Abstract: An investigation of the cognitive bias observed in optimism and the influence of optimism on psychological well-being was conducted. The cognitive bias was assumed to be related to the repressive style of information processing, represented by the trait scale of the State-Trait Anxiety Inventory and the Social Desirability scale. Optimism and well-being were measured by the Life Orientation Test and the Social Optimism scale as well as by the Life Satisfaction and Depression scales, respectively. These scales were applied to a sample of 200 individuals. Trait Anxiety and Social Desirability led to a high multiple correlation with the Life Orientation Test (R = .54) and a moderate multiple correlation with the Social Optimism scale (R = .30). Higher correlations were obtained for the expectation of a positive than of a negative future. Both the Life Orientation Test and the Social Optimism scale contributed to the high multiple correlation with psychological well-being (R = .52).

Effects of expectation and caffeine on arousal, well-being, and reaction time.

Abstract: The objective of this study is to determine the impact of expectation associated with placebo and caffeine ingestion. We used a three-armed, randomized, double-blind design. Two three-armed experiments varying instruction (true, false, control) investigated the role of expectations of changes in arousal (blood pressure, heart rate), subjective well-being, and reaction time (RT). In Experiment 1 (N = 45), decaffeinated coffee was administered, and expectations were produced in one group by making them believe they had ingested caffeinated coffee. In Experiment 2 (N = 45), caffeinated orange juice was given in both experimental groups, but only one was informed about the true content. In Experiment 1, a significant effect for subjective alertness was found in the placebo treatment compared to the control group. However, for RT and well-being no significant effects were found. In Experiment 2, no significant expectancy effects were found. Caffeine produced large effects for blood pressure in both treatments compared to the control group, but the effects were larger for the false information group. For subjective well-being (alertness, calmness), considerable but nonsignificant changes were found for correctly informed participants, indicating possible additivity of pharmacologic effect and expectations. The results tentatively indicate that placebo and expectancy effects primarily show through introspection.

The Toxicology of Mercury and Its Chemical Compounds

Abstract: This review covers the toxicology of mercury and its compounds. Special attention is paid to those forms of mercury of current public health concern. Human exposure to the vapor of metallic mercury dates back to antiquity but continues today in occupational settings and from dental amalgam. Health risks from methylmercury in edible tissues of fish have been the subject of several large epidemiological investigations and continue to be the subject of intense debate. Ethylmercury in the form of a preservative, thimerosal, added to certain vaccines, is the most recent form of mercury that has become a public health concern. The review leads to general discussion of evolutionary aspects of mercury, protective and toxic mechanisms, and ends on a note that mercury is still an "element of mystery."

Resilience: a historical review of the construct.

Abstract: Evolution of the construct of resilience from physiological and psychological research extends from the 1800s to the present. This review supports 3 observations: (1) the importance of a dynamic, interactive perspective for understanding resilience; (2) the complexity of the construct requires a holistic perspective; and (3) the importance of exposure to diverse experiences and educational perspectives for professional health care students.

Identification, Evaluation, and Management of Children With Autism Spectrum Disorder.

Abstract: Autism spectrum disorder (ASD) is a common neurodevelopmental disorder with reported prevalence in the United States of 1 in 59 children (approximately 1.7%). Core deficits are identified in 2 domains: social communication/interaction and restrictive, repetitive patterns of behavior. Children and youth with ASD have service needs in behavioral, educational, health, leisure, family support, and other areas. Standardized screening for ASD at 18 and 24 months of age with ongoing developmental surveillance continues to be recommended in primary care (although it may be performed in other settings), because ASD is common, can be diagnosed as young as 18 months of age, and has evidenced-based interventions that may improve function. More accurate and culturally sensitive screening approaches are needed. Primary care providers should be familiar with the diagnosticcriteria for ASD, appropriate etiologic evaluation, and co-occurring medical and behavioral conditions (such as disorders of sleep and feeding, gastrointestinal tract symptoms, obesity, seizures, attention-deficit/hyperactivity disorder, anxiety, and wandering) that affect the child’s function and quality of life. There is an increasing evidence base to support behavioral and other interventions to address specific skills and symptoms. Shared decision making calls for collaboration with families in evaluation and choice of interventions. This single clinical report updates the 2007 American Academy of Pediatrics clinical reports on the evaluation and treatment of ASD in one publication with an online table of contents and section view available through the American Academy of Pediatrics Gateway to help the reader identify topic areas within the report.

Intramuscular desferrioxamine in patients with Alzheimer's disease

Abstract: Although epidemiological and biochemical evidence suggests that aluminium may be associated with Alzheimer's disease (AD), there is no convincing proof of a causal link for aluminium in disease progression. We have completed a two year, single-blind study to investigate whether the progression of dementia could be slowed by the trivalent ion chelator, desferrioxamine. 48 patients with probable AD were randomly assigned to receive desferrioxamine (125 mg intramuscularly twice daily, 5 days per week, for 24 months), oral placebo (lecithin), or no treatment. No significant differences in baseline measures of intelligence, memory, or speech ability existed between groups. Activities of daily living were assessed and videorecorded at 6, 12, 18, and 24 month intervals. There were no differences in the rate of deterioration of patients receiving either placebo or no treatment. Desferrioxamine treatment led to significant reduction in the rate of decline of daily living skills as assessed by both group means (p = 0.03) and variances (p less than 0.04). The mean rate of decline was twice as rapid for the no-treatment group. Appetite (n = 4) and weight (n = 1) loss were the only reported side-effects. We conclude that sustained administration of desferrioxamine may slow the clinical progression of the dementia associated with AD.